Anticipating Medtronic’s Upcoming Quarterly Earnings Report

Medtronic plc is a leading company in the healthcare industry, focusing on developing, manufacturing, and selling device-based medical therapies to healthcare systems, physicians, clinicians, and patients. With a market cap of $126.4 billion, this Galway, Ireland-based company is preparing to reveal its fiscal Q3 earnings for 2026 on Tuesday, Feb. 17.

Analysts are anticipating a profit of $1.33 per share for Medtronic, which is a slight decrease of 4.3% from the previous year’s $1.39 per share. However, Medtronic has consistently exceeded Wall Street’s expectations in the past four quarters, with earnings of $1.36 per share in the previous quarter surpassing consensus estimates by 3.8%. Looking ahead to fiscal 2026, analysts project a profit growth to $5.64 per share, marking a 2.7% increase from the $5.49 per share reported in fiscal 2025. Further growth is expected in fiscal 2027, with an estimated EPS of $6.13, an 8.7% rise year-over-year.

Although Medtronic has slightly underperformed the S&P 500 Index’s 13.7% return in the last 52 weeks, the company’s shares have seen a 13.5% increase during the same period, outperforming the State Street Health Care Select Sector SPDR ETF’s 11.1% uptick.

Following the release of better-than-expected Q2 results on Nov. 18, Medtronic witnessed a 4.7% surge in its share price. The company reported a significant revenue increase of 6.6% year-over-year, reaching $9 billion, exceeding consensus estimates by 1.1%. Additionally, the adjusted EPS of $1.36 demonstrated a 7.9% growth from the previous year, beating analyst expectations of $1.31. Medtronic also raised its fiscal 2026 revenue growth and EPS guidance, contributing to enhanced investor confidence and underlining its positive performance.

Currently, Wall Street analysts hold a moderately optimistic outlook on Medtronic’s stock, with an overall “Moderate Buy” rating. Among 27 analysts covering the stock, 11 recommend a “Strong Buy,” while one suggests a “Moderate Buy,” and 15 indicate a “Hold.” The average price target for Medtronic is $110.71, implying a potential upside of 10.4% from the current levels. It is important to note that all information and data provided in this article are solely for informational purposes.